Latest News

Via The Motley Fool · February 7, 2025

Via The Motley Fool · February 7, 2025

The real estate investment trust's fourth-quarter report was generally in line with Wall Street's estimates.
Via The Motley Fool · February 7, 2025

PRLB earnings call for the period ending December 31, 2024.
Via The Motley Fool · February 7, 2025

Via The Motley Fool · February 7, 2025

Via The Motley Fool · February 7, 2025

Via The Motley Fool · February 7, 2025

The aggressive growth investor bought stocks heading in different directions this earnings season.
Via The Motley Fool · February 7, 2025

Via The Motley Fool · February 7, 2025

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates.
Via The Motley Fool · February 7, 2025

Via The Motley Fool · February 7, 2025

Cboe Global Markets posted record yearly revenue, yet fell short of quarterly estimates for Q4 2024.
Via The Motley Fool · February 7, 2025

Via The Motley Fool · February 7, 2025

Revenue numbers are up across the board, but weak guidance isn't sitting well with investors.
Via The Motley Fool · February 7, 2025